Merck & Co. stock after-hours at EUR 125.19: minus 2.16 percent
Published on 10/05/2026 at 19:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co. stock was at EUR 125.19 in after-hours trading at 7:21 p.m. CEST on October 5, 2026, according to Lang & Schwarz. The price was down 2.16 percent versus the prior close of EUR 127.96.
Merck stock during after-hours trading
The Lang & Schwarz price was EUR 125.19, compared with the previous trading day's close of EUR 127.96. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Merck stock.
Positive Phase 2b results for tulisokibart
In a September 30, 2026 release, Merck said its Phase 2b MK-7240-012 study of investigational tulisokibart met its primary endpoint in patients with moderate to severe hidradenitis suppurativa. At week 16, 72 percent of patients in the high-dose group and 64 percent in the medium-dose group achieved HiSCR50, compared with 35 percent in the placebo group. Merck said the data will inform Phase 3 development.
Exclusive license for preclinical cancer drug
On September 28, 2026, Business Wire reported that Merck and SciBrunch Therapeutics entered an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D inhibitor. Merck received worldwide development, manufacturing and commercialization rights. The agreement includes a $400 million upfront payment and potential milestone payments bringing the total possible transaction value to $2.13 billion. Merck said it will record a $400 million pretax charge in third-quarter 2026 results.
